Article Information
PubMed
Published By
History
- Received May 2, 2020
- Revision received September 15, 2020
- Accepted September 22, 2020
- First published December 2, 2020.
- Version of record published January 27, 2021.
Copyright & Usage
Copyright © 2021 the authors SfN exclusive license.
Author Information
- Marta De Felice1,2,
- Justine Renard1,2,
- Roger Hudson1,2,
- Hanna J. Szkudlarek1,2,
- Brian J. Pereira1,2,
- Susanne Schmid2,
- Walter J. Rushlow1,2,3, and
- Steven R. Laviolette1,2,3
- 1Addiction Research Group, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario N6A 5C1, Canada
- 2Department of Anatomy & Cell Biology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario N6A 3K7, Canada
- 3Department of Psychiatry, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario N6A 3K7, Canada
Author contributions
Author contributions: M.D.F. and S.R.L. designed research; M.D.F., J.R., R.H., H.J.S., B.J.P., and W.J.R. performed research; M.D.F., R.H., H.J.S., S.S., and W.J.R. analyzed data; M.D.F. and S.R.L. wrote the paper.
Disclosures
- Received May 2, 2020.
- Revision received September 15, 2020.
- Accepted September 22, 2020.
This work was supported by CanaQuest Medical Corp and MITACS Canada.
M.D.F. and S.R.L. declare that the results of this study have been included in intellectual property: U.S. Patent 62/730,253, “L-theanine and tetrahydrocannabinol formulation” (Provisional filled September 12, 2018). The authors declare no other competing financial interests.
- Correspondence should be addressed to Steven R. Laviolette at steven.laviolette{at}schulich.uwo.ca
Funding
Mitacs
CanaQuest Medical Corp
Other Version
- previous version (December 02, 2020).
- You are viewing the most recent version of this article.
